Poxel
Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Poxel SA is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases. The company's pipeline includes two mid-stage candidates: PXL065 for non-alcoholic steatohepatitis (NASH) and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. Poxel also developed TWYMEEG® (Imeglimin), a treatment for type 2 diabetes that is approved and marketed in Japan by its partner, Sumitomo Pharma, from which Poxel receives royalties and sales-based payments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-08 17:45 |
Delisting Announcement
Inside Information / Other news releases
|
English | 109.8 KB | ||
| 2025-08-08 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 96.7 KB | ||
| 2025-08-01 07:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 134.8 KB | ||
| 2025-08-01 07:30 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 164.3 KB | ||
| 2025-07-08 18:46 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 110.8 KB | ||
| 2025-06-30 18:32 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 109.4 KB | ||
| 2025-06-30 18:32 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 95.0 KB | ||
| 2025-06-06 19:05 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 76.2 KB | ||
| 2025-05-28 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 95.0 KB | ||
| 2025-05-28 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 119.8 KB | ||
| 2025-05-26 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 98.0 KB | ||
| 2025-05-26 18:00 |
Environmental & Social Information
Informations privilégiées / Autres communiqués
|
French | 86.7 KB | ||
| 2025-05-13 07:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 153.8 KB | ||
| 2025-05-13 07:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 130.6 KB | ||
| 2025-05-06 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 84.4 KB |
Automate Your Workflow. Get a real-time feed of all Poxel filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Poxel via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
